Cystic Fibrosis Therapeutics Market Overview:
Cystic
fibrosis is a hereditary disorder, which majorly affects lungs and other body
parts such as pancreas, liver, and kidney. It is caused by the mutation in the
cystic fibrosis transmembrane conductance regulator (CFTR) gene. This gene is
located in chromosome number 7, and is responsible for the regulation of sweat,
mucus, and body secretions. However, mutation of this gene leads to absence of
CFTR activity, which in turn results in loss of chloride and alters the protein
structure. Patients experience difficulty in breathing, mucus formation, fatty
stool, and difficulty in the passageway of the pancreas, bile duct, intestine,
& salivary gland. Cystic fibrosis is diagnosed by the use of sweat test and
genetic testing. Physical therapy is used for the treatment of cystic fibrosis
that helps in the reduction of mucus formation and fights against infections of
an organ. In addition, treatment of cystic fibrosis includes the use of drugs
such as Pulmozyme, Kalydeco, and others. These drugs can be administered to the
patient by different routes such as oral and by inhalation.
Request
Sample Report: https://www.alliedmarketresearch.com/request-sample/5499
The global
cystic fibrosis therapeutic market is segmented on the basis of drug class,
route of administration, top selling drug, and region. On the basis of drug
class, the market is divided into pancreatic enzyme supplements, mucolytic,
bronchodilators, and CFTR modulators. Depending on route of administration, it
is classified into oral and inhaled. By top selling drug, the market is
segregated into pulmozyme, Creon, kalydeco, cayston, azithromycin, tobramycin
and others. Region wise, it is analyzed across North America, Europe,
Asia-Pacific, and LAMEA.
Europe constitutes the
highest market share in the global cystic fibrosis therapeutics market in 2018,
followed by North America owing to the increase in incidence of cystic
fibrosis. Moreover, increase in governmental support for innovation and rise in
funding of projects for R&D of various cystic fibrosis drugs further fuel
the market growth in this region. UK is the highest revenue contributor due to
increase in prevalence of cystic fibrosis in this region. Moreover, surge in
national newborn screening program in the UK propels the market growth. In
addition, many companies are involved in developing drugs for individuals who
do not get benefitted with CFTR drugs. However, North America is projected to
grow at the highest CAGR during the forecast period.
Key players operating in cystic
fibrosis therapeutic markets are Genentech, Inc., Novartis AG, Gilead Sciences,
Inc., Vertex Pharmaceuticals Incorporated, AbbVie Inc., GlaxoSmithKline Plc.,
Johnson & Johnson, Allergan plc, Pharmaxis Ltd., and Mylan N.V.
Key Benefits for Cystic Fibrosis Therapeutics Market:
- The cystic fibrosis therapeutics market share is based on a comprehensive analysis of key developments in the cystic fibrosis industry.
- The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the global cystic fibrosis therapeutics market.
- The cystic fibrosis therapeutics market trends are studied from 2018 to 2026.
- Information about key drivers, restrains, and opportunities and their impact analysis on the cystic fibrosis therapeutics market size is provided.
- Porter’s five forces analysis illustrates the potency of buyers and suppliers operating in the industry.
- The quantitative analysis of the global cystic fibrosis therapeutics market forecast from 2019 to 2026 is provided to determine the market potential.
0 Comments